Hoth Therapeutics signs term sheet with Zylo Therapeutics
Hoth Therapeutics announced that the company has signed a term sheet with Zylo Therapeutics to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus, or CLE. CLE is a chronic autoimmune disease that affects the skin. The work at Einstein supports the thesis that AEA loaded into Z-pods improves drug skin penetration, reduces the expected inflammatory cytokine secretion by keratinocytes when exposed to ultraviolet radiation, prevents the development of CLE skin lesions, improves skin histopathology, prevents inflammation and structural damage on histology and reduces macrophages and C3 accumulation. The term sheet is non-binding and neither party thereto shall have any obligation to consummate a transaction of any kind until such time as the parties have entered into a mutually agreeable definitive agreement. There can be no assurance that any such definitive agreement will be entered into or that the transaction will be completed on the terms set forth in the term sheet, or at all.